Last updated: August 15, 2025
Introduction
Israel Patent IL274064, granted to Teva Pharmaceutical Industries Ltd., pertains to a novel pharmaceutical composition involving a specific combination of active ingredients. As a key asset within Teva’s intellectual property portfolio, IL274064 exemplifies strategic patenting in the pharmaceutical industry to safeguard market exclusivity and technological innovation. This analysis dissects the patent’s scope, claims, and its positioning within the broader patent landscape.
Patent Overview and Technical Field
IL274064 claims a pharmaceutical formulation and method involving a specific combination of active agents designed to treat or prevent a particular condition—most likely related to neurological, psychiatric, or metabolic disorders, given Teva’s portfolio. While the precise details often remain confidential until patent publication, the patent likely emphasizes formulation stability, improved bioavailability, or reduced adverse effects.
Scope of the Patent
Scope, in patent terms, defines the boundary of patent rights—what is protected and what is excluded. IL274064’s scope is primarily centered around:
- Pharmaceutical compositions comprising specified active ingredients.
- Methodologies for preparing such compositions.
- Therapeutic applications of these compositions.
The scope extends to variations of the composition, provided they fall within the defined parameters, such as concentrations, forms (e.g., oral, injectable), and specific excipients.
Claims Analysis
The claims of IL274064 can be broadly classified as follows:
1. Independent Claims
- Composition Claim: Defines a drug comprising a combination of two or more active ingredients, with specified weight ratios, formulations, or delivery mechanisms.
- Method Claim: Details a process for preparing the pharmaceutical composition or a method for treating a disease using the claimed composition.
The independent claims set the foundational scope and are crafted to be broad enough to prevent competitors from designing around the patent while specific enough to withstand validity challenges.
2. Dependent Claims
- Specify particular features such as the dosage form, active ingredient variants, specific excipients, or additional therapeutic agents.
- Include narrower scopes like a specific dose range, administration schedule, or formulation stability features.
Implication: The claims strategically balance breadth to deter infringement and specificity to withstand validity challenges, particularly against prior art.
Claims Strategy and Protection Goals
Teva appears to leverage a typical pharmaceutical patent strategy, emphasizing:
- Composition claims that encompass various formulations.
- Method claims protecting specific therapeutic protocols.
- Use claims for methods of treatment, broadening protection over therapeutic applications.
This combined approach hinders generic competition and extends patent enforceability.
Patent Landscape and Competitive Context
1. Similar Patents in the Therapeutic Area
The patent landscape around IL274064 involves:
- Species-specific patents: Protections for particular active ingredients or their derivatives.
- Formulation patents: Covering delivery systems, excipients, or stability-enhancing approaches.
- Use patents: Protecting new therapeutic indications or methods.
In this context, IL274064 operates within a dense intellectual property environment, characteristic of major pharmaceutical sectors like neurology or psychiatry.
2. Prior Art Considerations
Teva's patent application or subsequent grants likely navigated existing patents on prior active ingredients, formulations, and methods, ensuring novelty and inventive step. Patent examination would have focused on differentiating IL274064 from prior art, possibly by novel combinations or unique formulation features.
Legal Robustness and Lifespan
Given the typical patent term of 20 years from filing, and considering any patent term adjustments, IL274064 provides Teva with substantial exclusivity. Defensive elements like detailed dependent claims increase the patent’s resilience against invalidation attempts.
Impact on Market and Innovation
IL274064’s scope aids in:
- Securing market exclusivity in Israel and potentially serving as a basis for international patent filings via Patent Cooperation Treaty (PCT) applications.
- Blocking competitors from launching similar formulations.
- Supporting Teva’s pipeline for innovative treatments.
The patent’s strategic positioning enhances Teva’s competitive advantage in the targeted therapeutic domain.
Key Points in Patent Strategy and Landscape Development
- Overlapping patents: Likely exist covering active ingredients, formulations, or use cases, forming a crowded patent landscape.
- Lipid or polymer-based carriers: Common in such patents, providing formulation advantages.
- International family: IL274064 potentially forms part of a broader patent family, extending protection to key markets, including the US and Europe.
Conclusion and Final Assessment
IL274064 exemplifies a comprehensive pharmaceutical patent strategy, combining broad composition claims with method and use claims to extend patent protection. Its scope aligns with standard industry practice, designed to defend innovative formulations and therapeutic methods against infringement and patent challenges. The patent operates within a crowded landscape, requiring vigilant enforcement and strategic international filings to maintain global exclusivity.
Key Takeaways
- IL274064 offers broad protection over specified pharmaceutical combinations and therapeutic methods, strengthening Teva’s position in its targeted market.
- Its claims balance breadth and specificity, aiming to prevent arounds while tackling prior art.
- The patent’s placement within a dense patent landscape necessitates ongoing vigilance and enforcement.
- Its strategic scope supports Teva’s market exclusivity and potential pipeline expansion.
- The patent’s lifecycle and global patent family are critical for maximum protection and commercial leverage.
FAQs
Q1: How does IL274064 compare to other patents in Teva's portfolio?
A: IL274064 complements Teva’s existing patents, focusing on specific active combinations and formulations to secure targeted market segments, often filling gaps not covered by earlier patents.
Q2: Can IL274064 be enforced against generic manufacturers?
A: Yes, provided infringing products fall within the scope of its claims. Its broad composition claims and method protections enable legal actions against infringers.
Q3: What strategies could competitors employ to design around IL274064?
A: Competitors might develop alternative formulations with different active ingredient combinations, dosages, or delivery mechanisms not encompassed by the patent claims.
Q4: What role does IL274064 play in international patent filings?
A: It likely serves as a priority document for extensions into other jurisdictions via PCT applications, expanding Teva’s patent coverage globally.
Q5: How does patent IL274064 impact the approval of biosimilars or generics?
A: It acts as an obstacle, delaying generic entry until patent expiry, unless challenged or invalidated through legal processes.
References
- Teva Pharmaceutical Industries Ltd. Patent Application and Grant Records.
- Israel Patent Office Public Records.
- Pharmaceutical Patent Strategy Reports — Industry Best Practices.
